These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19764095)

  • 1. Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population.
    Dahlan Y; Ather HM; Al-ahmadi M; Batwa F; Al-hamoudi W
    World J Gastroenterol; 2009 Sep; 15(35):4429-33. PubMed ID: 19764095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.
    Takita M; Hagiwara S; Arizumi T; Hayaishi S; Ueda T; Kitai S; Yada N; Inoue T; Minami Y; Chung H; Ueshima K; Sakurai T; Kudo M
    Digestion; 2011; 84 Suppl 1():56-61. PubMed ID: 22156487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
    Yu JW; Sun LJ; Zhao YH; Kang P; Gao J; Li SC
    Liver Int; 2009 Nov; 29(10):1485-93. PubMed ID: 19602134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.
    Dahari H; Affonso de Araujo ES; Haagmans BL; Layden TJ; Cotler SJ; Barone AA; Neumann AU
    J Hepatol; 2010 Sep; 53(3):460-7. PubMed ID: 20561702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.
    Zopf S; Herold C; Hahn EG; Ganslmayer M
    Scand J Gastroenterol; 2009; 44(4):486-90. PubMed ID: 19117241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
    Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
    Ferenci P; Laferl H; Scherzer TM; Gschwantler M; Maieron A; Brunner H; Stauber R; Bischof M; Bauer B; Datz C; Löschenberger K; Formann E; Staufer K; Steindl-Munda P;
    Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
    Harrison SA; Abdurakhmanov D; Shiffman ML; Bakulin I; Mazur W; Rodriguez-Torres M; Silva GF; Cheinquer H; Messinger D; Connell EV; McKenna M; Tatsch F; Reddy KR;
    J Clin Gastroenterol; 2013 Mar; 47(3):271-9. PubMed ID: 22951527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of individualized treatment for hepatitis C patients in the real world.
    Chen TM; Huang PT; Lin CH; Tsai MH; Lin LF; Liu CC; Ho KS; Tung JN
    J Gastroenterol Hepatol; 2010 Jan; 25(1):61-9. PubMed ID: 19780879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
    Vigani AG; Gonçales ES; Pavan MH; Genari F; Tozzo R; Lazarini MS; Fais V; Feltrin A; Gonçales NS; Gonçales FL
    Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.
    Al-Hamoudi W; Mohamed H; Abaalkhail F; Kamel Y; Al-Masri N; Allam N; Alqahtani S; Al-Sofayan M; Khalaf H; Al-Sebayel M; Al-Jedai A; Abdo A
    Dig Dis Sci; 2011 Jun; 56(6):1848-52. PubMed ID: 21221800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C].
    Lee HJ; Eun JR; Choi JW; Kim KO; Moon HJ
    Korean J Hepatol; 2008 Mar; 14(1):46-57. PubMed ID: 18367857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
    Mecenate F; Pellicelli AM; Barbaro G; Romano M; Barlattani A; Mazzoni E; Bonaventura ME; Nosotti L; Arcuri P; Picardi A; Barbarini G; D'Ambrosio C; Paffetti A; Andreoli A; Soccorsi F;
    BMC Gastroenterol; 2010 Feb; 10():21. PubMed ID: 20170514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.